Saniona AB
Research Saniona AB (SANION) on Bullrun: valuation model: 37.7% undervalued, market cap SEK 1.76B, P/E 8.0. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSANION
- ExchangeST
- CountryDenmark
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Valuation signal37.7% undervalued
- Market capSEK 1.76B
- P/E8.0
- Financial periodFY2024
- RevenueSEK 334.67M
- Revenue growth1887.4%
- Net incomeSEK 188.71M
- Free cash flowSEK 248.05M
Valuation Snapshot
Bullrun's latest valuation model marks Saniona AB as 37.7% undervalued; latest market cap is SEK 1.76B; P/E is 8.0.
About Saniona AB
Saniona AB (publ), a clinical-stage biopharmaceutical company, focuses on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders in Ireland, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity;
Frequently asked questions
Is Saniona AB overvalued or undervalued?
Bullrun's valuation model currently marks Saniona AB as 37.7% undervalued.
What is Saniona AB's market cap?
Saniona AB's market capitalization is SEK 1.76B.
What is Saniona AB's P/E ratio?
Saniona AB's price-to-earnings (P/E) ratio is 8.0.
What does Saniona AB do?
Saniona AB (publ), a clinical-stage biopharmaceutical company, focuses on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders in Ireland, the United States, Germany, Denmark, and the United Kingdom.